Neuroscios
Neuroscios is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Effects of Dopaminergic Therapy in Patients with Alzheimer's Disease: A 24 weeks prospective, randomized, double-blind, placebo-controlled, parallel group, international, multi-center phase III study evaluating efficacy and safety of rotigotine 4mg/24 hrs in combination with rivastigmine 9.5 mg/24 hrs in mild to moderate Alzheimer's disease patients.
Sponsor Fondazione Santa Lucia IRCCS
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II Clinical Trial to Evaluate the Safety and Feasibility of Senolytic Therapy in Alzheimer's Disease: "Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD)" Study
Sponsor Wake Forest University Health Sciences
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Neuroscios?
The 2026-10-09 snapshot links Neuroscios to 2 distinct CTIS trials. Recorded services include Clinical monitoring, Investigator recruitment, Project management, Quality assurance & auditing, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Neuroscios?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Neuroscios conducted?
The linked trials record locations in 4 countries, including Spain, Czechia, Germany, Italy. These are trial locations, not confirmed office locations or countries where Neuroscios delivered services.
What can this page tell me about Neuroscios's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Neuroscios. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Neuroscios GmbH